CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/β-catenin pathway
16
Citation
36
Reference
10
Related Paper
Citation Trend
Abstract:
Background: CDK12 is a potential therapeutic target in papillary thyroid cancer that regulates the c-myc/β-catenin pathway. Objective: We aimed to explore the specific mechanism of CDK12 in papillary thyroid cancer and provide a new target of cancer therapy. Methods: RT-qPCR was used to determine the CDK12 mRNA expression level. An IHC assay was performed to detect the tissue expression of CDK12. Then, we downregulated CDK12 expression in the thyroid cancer cell lines TPC-1-shCDK12 and KAT-5-shCDK12. CCK8 assays, colony formation assays, and animal xenograft models were used to evaluate the effect of CDK12 on tumorigenesis. Transwell assays and in vivo metastasis models were used to observe whether CDK12 can promote cancer metastasis. Western blotting further confirmed the mechanism of CDK12 in papillary thyroid cancer through the c-myc/β-catenin pathway. Results: Upregulated CDK12 expression in papillary thyroid cancer promoted papillary thyroid cancer carcinogenesis in vivo, and in vitro CDK12 strengthened papillary thyroid cancer (PTC) cell migration and tumor metastasis. CDK12 promoted tumor progression by regulating c-myc/β-catenin pathway activation. Conclusions: CDK12 affects the c-myc/β-catenin pathway to stimulate papillary thyroid cancer proliferation and metastasis. Inhibiting CDK12 might be a new method in papillary thyroid cancer therapy.Keywords:
Tumor progression
Introduction: It has been identified ionizing radiation as the definitive cause of cancer in humans. One third of the tumors that develop after radiation exposure are malignant, with papillary thyroid cancer (PTC) being the most common cancer type. This study aimed to investigate the relationship between total radiation dose (TRD) received during imaging tests and thyroid cancer occurrence in patients diagnosed with PTC.
Material and Method: The study was designed to retrospectively review the data of adult patients aged ≥ 18 years who were diagnosed with PTC between 2005 and 2022. Patients diagnosed with a condition other than PTC were excluded from the study
Result: 307 patients with papillary thyroid cancer were 256 (83.4%) women, with a mean age of 44.7 ± 13.5 years. A statistically significant relationship was observed between TRD and multifocality (p = 0.02). Tumor size (r = 0,2, p = 0.07) weakly correlated with TRD. And TRD (OR: 0.9, 95% CI: 1.0-1.1, p: 0.006) according to multifocalty were found to be significant.
Discussion: This study found an association between TRD taken during imaging tests and multifocality. As a result, the authors aimed to remind clinicians that the disease may progress more aggressively and that thyroid cancer may develop in patients exposed to radiation as a result of excessive imaging tests
Cite
Citations (0)
目的：探讨 Wnt/β-catenin 信号通路 Wnt-7a、Frlzzled、β-catenin 和 MMP-9基因在子宫内膜异位症患者在位内膜组织、异位内膜组织和正常子宫内膜组织的表达及其意义。方法采用免疫组织化学 SP 方法和Western blot 方法分别检测子宫内膜异位症患者在位内膜组织、异位内膜组织和正常子宫内膜组织中 Wnt-7a、Fr-lzzled、β-catenin 和 MMP-9基因蛋白质表达水平；用实时定量 RT-PCR 方法检测 Wnt-7a、Frlzzled、β-catenin 和MMP-9基因的 mRNA 表达水平。结果免疫组织化学实验显示，Wnt-7a 在3种内膜组织中均无表达，3种不同组织的内膜中 Frizzled、β-catenin 和 MMP-9蛋白质在异位组织表达明显高于正常内膜组织（P ＜0．01）；在异位内膜组织表达明显高于在位内膜组织（P ＜0．05）。Western blot 实验显示 Wnt-7a、Frizzled、β-catenin 和 MMP-9在子宫内膜异位组织蛋白质表达水平高于正常子宫内膜组织和在位子宫内膜组织。Wnt-7a、Frlzzled、β-catenin 和MMP-9基因 mRNA 表达水平异位内膜组织高于在位内膜组织和正常内膜组织，Wnt-7a、Frlzzled、β-catenin 基因mRNA 表达水平在位内膜组织高于正常内膜组织，MMP-9基因 mRNA 表达水平在位内膜组织低于正常内膜组织。结论Wnt/β-catenin 信号通路 Wnt-7a、Frlzzled、β-catenin 和 MMP-9基因可能共同参与了子宫内膜异位症的发生，并且β-catenin 可能通过对上游 Wnt-7a、Frizzled 和下游信号靶基因 MMP-9mRNA 的传导调控成为子宫内膜异位症疾病发展过程中的作用机制。
LRP6
LRP5
Beta-catenin
Cite
Citations (0)
The Wnt/β-catenin signaling pathway plays a major role in tissue homeostasis, and its dysregulation can lead to various human diseases. Aberrant activation of β-catenin is oncogenic and is a critical driver in the development and progression of human cancers. Despite the significant potential of targeting the oncogenic β-catenin pathway for cancer therapy, the development of specific inhibitors remains insufficient. Using a T cell factor (TCF)-dependent luciferase-reporter system, we screened for small-molecule compounds that act against Wnt/β-catenin signaling and identified MSAB (methyl 3-{[(4-methylphenyl)sulfonyl]amino}benzoate) as a selective inhibitor of Wnt/β-catenin signaling. MSAB shows potent anti-tumor effects selectively on Wnt-dependent cancer cells in vitro and in mouse cancer models. MSAB binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. Our findings might represent an effective therapeutic strategy for cancers addicted to the Wnt/β-catenin signaling pathway.
Beta-catenin
LRP5
Cite
Citations (116)
Background: The incidence of thyroid cancer has increased worldwide. The country where the incidence has increased most is South Korea. The goal of this study is to understand the magnitude of association between opportunistic thyroid cancer screening and thyroid cancer incidence, thyroid cancer subtype, and disease-specific mortality. Methods: We used the 2010 Korea Community Health Survey, which queried 226,873 individuals if they had been screened for thyroid cancer in the last two years. Thyroid cancer incidence data from 2008 to 2010 were obtained from the Korea Cancer registry data, and mortality data from 2007–2010 were obtained from the Statistics Korea database. The ecological association between thyroid screening and thyroid cancer incidence and mortality by age and sex were examined across Korea's 16 administrative regions by general linear regression models. Results: Between 2008 and 2010, the incidence of thyroid cancer was 64.1 per 100,000 individuals: the incidence in females was 107.3 and in males was 21.1. There was a strong positive correlation between regional thyroid cancer screening and regional thyroid cancer incidence (r = 0.77, [95% confidence interval 0.70–0.82]). The magnitude of correlation was higher for females (r = 0.88 [CI 0.83–0.92]) than in males (r = 0.76 [CI 0.67–0.84]) in any age group. Thyroid screening was only associated with increased detection of papillary thyroid cancer (r = 0.74 [CI 0.59–0.88]); and not associated with mortality (r = −0.08 [CI −0.59–0.63]) due to thyroid cancer. Conclusions: The magnitude of association between thyroid cancer screening in South Korea and the incidence of thyroid cancer strongly suggests that screening is the most important driver of the epidemic of thyroid cancer, particularly among females. Thyroid cancer screening, however, was only associated with the increase of one tumor histology, papillary thyroid cancer, and it did not have any association with thyroid cancer mortality. The extent to which opportunistic thyroid cancer screening is converting thousands of asymptomatic persons to cancer patients without any known benefit to them needs to be examined carefully.
Thyroid disease
Cite
Citations (196)
Thyroid cancer (TC) is the most common malignant tumor of the endocrine glands and accounts to 3% of the total structure of oncological morbidity. Papillary thyroid cancer (PTC) is the most common histological variant of thyroid malignancies. It accounts for about 85% of all cases of thyroid cancer. Despite good postoperative results and excellent survival compared to many other malignancies, tumor metastases to the paratracheal lymph nodes are quite common. This review of the literature considers the current personalized approach to patients with papillary thyroid cancer and current aspects influencing the management of patients with PTC.Рак щитовидной железы (РЩЖ) является наиболее частой злокачественной опухолью эндокринных желез и составляет до 3% в общей структуре онкологической заболеваемости. Папиллярный рак щитовидной железы (ПРЩЖ) является наиболее частым гистологическим вариантом злокачественных новообразований щитовидной железы, на его долю приходится около 85% всех случаев РЩЖ. Несмотря на благоприятные послеоперационные результаты и высокую выживаемость по сравнению со многими другими злокачественными заболеваниями, метастазы опухоли в паратрахеальные лимфатические узлы встречаются довольно часто. В обзоре литературы рассмотрен современный персонализированный подход к пациентам с ПРЩЖ и аспекты, влияющие на тактику ведения.
Cite
Citations (2)
Background: Thyroid cancer is the most common endocrine tumor and is increasing in incidence. The aim of this study was to review mouse models of differentiated thyroid cancer and how they elucidate human thyroid cancer biology. Summary: Differentiated thyroid cancer, primarily papillary and follicular, comprises the majority of thyroid cancers. There has been tremendous growth in the cross-talk between basic science and clinical practice for thyroid cancer management. Insight into the framework of genes responsible for differentiated thyroid cancer has been gained through the use of mouse models. Common genetic alterations found in human papillary thyroid cancer such as RET/PTC rearrangements or the BRAFV600E mutation have genetically modified mouse counterparts. These and other preclinical mouse models have validated the importance of the cyclic adenosine monophosphate (cAMP)/protein kinase A and mitogen-activated protein kinase (MAPK) signaling pathways in papillary thyroid cancer (PTC). RAS mutations have a role in both papillary and follicular thyroid cancer development. Mice with overactivation of the phosphatidylinol-3-kinase (PI3K)–AKT and/or thyrotropin-regulated signaling pathways have been found to develop follicular thyroid cancer. Additional mouse models of thyroid cancer that utilize inducible expression systems are in development or are being characterized and will better reflect the majority of human thyroid cancers which are non-hereditary. Advances in in vivo imaging of mice allow for earlier detection of metastasis and the ability to follow tumor growth or regression which may be used in evaluation of pharmaceutical agents. Conclusions: Mouse models have expanded our understanding of the altered signaling pathways that contribute to thyroid cancer tumorigenesis and provide a powerful tool to develop novel diagnostic approaches and therapies.
Follicular thyroid cancer
Anaplastic thyroid cancer
Cite
Citations (50)
Background: CDK12 is a potential therapeutic target in papillary thyroid cancer that regulates the c-myc/β-catenin pathway. Objective: We aimed to explore the specific mechanism of CDK12 in papillary thyroid cancer and provide a new target of cancer therapy. Methods: RT-qPCR was used to determine the CDK12 mRNA expression level. An IHC assay was performed to detect the tissue expression of CDK12. Then, we downregulated CDK12 expression in the thyroid cancer cell lines TPC-1-shCDK12 and KAT-5-shCDK12. CCK8 assays, colony formation assays, and animal xenograft models were used to evaluate the effect of CDK12 on tumorigenesis. Transwell assays and in vivo metastasis models were used to observe whether CDK12 can promote cancer metastasis. Western blotting further confirmed the mechanism of CDK12 in papillary thyroid cancer through the c-myc/β-catenin pathway. Results: Upregulated CDK12 expression in papillary thyroid cancer promoted papillary thyroid cancer carcinogenesis in vivo, and in vitro CDK12 strengthened papillary thyroid cancer (PTC) cell migration and tumor metastasis. CDK12 promoted tumor progression by regulating c-myc/β-catenin pathway activation. Conclusions: CDK12 affects the c-myc/β-catenin pathway to stimulate papillary thyroid cancer proliferation and metastasis. Inhibiting CDK12 might be a new method in papillary thyroid cancer therapy.
Tumor progression
Cite
Citations (16)
β catenin belongs to the armadillo family of proteins. It plays a crucial role in developmental and homeostatic processes. Wnts are a family of 19 secreted glycoproteins that transduce multiple signaling cascades, including the canonical Wnt/β catenin pathway, Wnt/Ca2+ pathway and the Wnt/polarity pathway. This is a review on β catenin, Wnt proteins and their secretion, the signaling pathway, the associated factors and the crucial role of β catenin in odontogenesis.
LRP6
LRP5
Beta-catenin
Cite
Citations (23)
Thyroid cancer (TC) includes tumors of follicular cells; it ranges from well differentiated TC (WDTC) with generally favorable prognosis to clinically aggressive poorly differentiated TC (PDTC) and undifferentiated TC (UTC). Papillary thyroid cancer (PTC) is a WDTC and the most common type of thyroid cancer that comprises almost 70-80% of all TC. PTC can present as a solid, cystic, or uneven mass that originates from normal thyroid tissue. Prognosis of PTC is excellent, with an overall 10-year survival rate >90%. However, more than 30% of patients with PTC advance to recurrence or metastasis despite anti-cancer therapy; consequently, systemic therapy is limited, which necessitates expansion of improved clinical approaches. We strived to elucidate genetic distinctions due to patient-derived anti-cancer drug-sensitive or -resistant PTC, which can support in progress novel therapies. Patients with histologically proven PTC were evaluated. PTC cells were gained from drug-sensitive and -resistant patients and were compared using mRNA-Seq. We aimed to assess the in vitro and in vivo synergistic anti-cancer effects of a novel combination therapy in patient-derived refractory PTC. This combination therapy acts synergistically to promote tumor suppression compared with either agent alone. Therefore, genetically altered combination therapy might be a novel therapeutic approach for refractory PTC.
Follicular thyroid cancer
Refractory (planetary science)
Cite
Citations (8)
Thyroid cancer incidence has increased substantially in the United States over the last 4 decades, driven largely by increases in papillary thyroid cancer. It is unclear whether the increasing incidence of papillary thyroid cancer has been related to thyroid cancer mortality trends.To compare trends in thyroid cancer incidence and mortality by tumor characteristics at diagnosis.Trends in thyroid cancer incidence and incidence-based mortality rates were evaluated using data from the Surveillance, Epidemiology, and End Results-9 (SEER-9) cancer registry program, and annual percent change in rates was calculated using log-linear regression.Tumor characteristics.Annual percent changes in age-adjusted thyroid cancer incidence and incidence-based mortality rates by histologic type and SEER stage for cases diagnosed during 1974-2013.Among 77 276 patients (mean [SD] age at diagnosis, 48 [16] years; 58 213 [75%] women) diagnosed with thyroid cancer from 1974-2013, papillary thyroid cancer was the most common histologic type (64 625 cases), and 2371 deaths from thyroid cancer occurred during 1994-2013. Thyroid cancer incidence increased, on average, 3.6% per year (95% CI, 3.2%-3.9%) during 1974-2013 (from 4.56 per 100 000 person-years in 1974-1977 to 14.42 per 100 000 person-years in 2010-2013), primarily related to increases in papillary thyroid cancer (annual percent change, 4.4% [95% CI, 4.0%-4.7%]). Papillary thyroid cancer incidence increased for all SEER stages at diagnosis (4.6% per year for localized, 4.3% per year for regional, 2.4% per year for distant, 1.8% per year for unknown). During 1994-2013, incidence-based mortality increased 1.1% per year (95% CI, 0.6%-1.6%) (from 0.40 per 100 000 person-years in 1994-1997 to 0.46 per 100 000 person-years in 2010-2013) overall and 2.9% per year (95% CI, 1.1%-4.7%) for SEER distant stage papillary thyroid cancer.Among patients in the United States diagnosed with thyroid cancer from 1974-2013, the overall incidence of thyroid cancer increased 3% annually, with increases in the incidence rate and thyroid cancer mortality rate for advanced-stage papillary thyroid cancer. These findings are consistent with a true increase in the occurrence of thyroid cancer in the United States.
Cite
Citations (1,829)